Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Block listing Interim Review

13 Nov 2024 15:00

RNS Number : 9611L
GSK PLC
13 November 2024
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 13 November 2024

 

Name of applicant:

GSK plc

Name of scheme:

GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2024

To:

31 October 2024

Balance of unallotted securities under scheme(s) from previous return:

115,518

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G):

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

115,518

 

 

Name of applicant:

GSK plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2024

To:

31 October 2024

Balance of unallotted securities under scheme(s) from previous return:

673,024

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G):

155,786

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

517,238

 

 

Name of applicant:

GSK plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2022

Period of return:

From:

1 May 2024

To:

31 October 2024

Balance of unallotted securities under scheme(s) from previous return:

995,257

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G):

19,867

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

975,390

 

 

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRDLLFFZFLBFBF
Date   Source Headline
25th Jul 20257:00 amRNSTransaction in Own Shares
24th Jul 20255:00 pmRNSBlenrep approved in the EU for multiple myeloma
24th Jul 20257:00 amRNSTransaction in Own Shares
23rd Jul 20255:00 pmRNSUS FDA review extended for Blenrep
23rd Jul 20257:00 amRNSTransaction in Own Shares
22nd Jul 20257:00 amRNSTransaction in Own Shares
21st Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20253:30 pmRNSDirector/PDMR Shareholding
18th Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20257:00 amRNSBlenrep US ODAC outcome
17th Jul 20257:00 amRNSGSK’s Shingrix Fully Liquid FDA approval
17th Jul 20257:00 amRNSTransaction in Own Shares
16th Jul 20257:00 amRNSTransaction in Own Shares
15th Jul 20253:30 pmRNSDirector/PDMR Shareholding
15th Jul 20257:00 amRNSTransaction in Own Shares
14th Jul 20253:30 pmRNSDirector/PDMR Shareholding
14th Jul 20257:00 amRNSGSK submits Arexvy for adults 18-49 AIR to FDA
14th Jul 20257:00 amRNSTransaction in Own Shares
11th Jul 20257:00 amRNSTransaction in Own Shares
10th Jul 20257:00 amRNSTransaction in Own Shares
9th Jul 20257:00 amRNSTransaction in Own Shares
8th Jul 20257:00 amRNSTransaction in Own Shares
7th Jul 20254:00 pmRNSGSK completes acquisition of efimosfermin for SLD
7th Jul 20257:00 amRNSTransaction in Own Shares
4th Jul 20257:00 amRNSTransaction in Own Shares
3rd Jul 20257:00 amRNSTransaction in Own Shares
2nd Jul 20257:00 amRNSTransaction in Own Shares
1st Jul 20253:00 pmRNSTotal Voting Rights
1st Jul 20257:00 amRNSTransaction in Own Shares
30th Jun 20257:00 amRNSTransaction in Own Shares
27th Jun 20257:00 amRNSTransaction in Own Shares
26th Jun 20257:00 amRNSTransaction in Own Shares
25th Jun 20257:00 amRNSTransaction in Own Shares
24th Jun 20253:30 pmRNSDirector/PDMR Shareholding
24th Jun 20253:00 pmRNSDirector Declaration
24th Jun 20257:00 amRNSTransaction in Own Shares
23rd Jun 20255:50 pmRNSReplacement - Director/PDMR Shareholding
23rd Jun 20253:30 pmRNSDirector/PDMR Shareholding
23rd Jun 20258:30 amRNSReplacement RNS: Linerixibat file accepted by EMA
23rd Jun 20258:18 amRNSGSK Submits Arexvy for adults 18+ with EMA
23rd Jun 20257:00 amRNSTransaction in Own Shares
20th Jun 20257:00 amRNSArexvy filed in Japan for 18-49 at increased risk
20th Jun 20257:00 amRNSTransaction in Own Shares
19th Jun 20257:00 amRNSTransaction in Own Shares
18th Jun 20257:00 amRNSTransaction in Own Shares
17th Jun 20257:00 amRNSTransaction in Own Shares
16th Jun 20257:00 amRNSTransaction in Own Shares
13th Jun 20253:30 pmRNSDirector/PDMR Shareholding
13th Jun 20257:00 amRNSTransaction in Own Shares
13th Jun 20257:00 amRNSGSK submits Arexvy for adults 18+ with EMA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.